VivoSeq
Other

Gingivitis

30

Pipeline Programs

12

Active Trials

10

Companies Involved

Gingivitis is an emerging landscape with 30 programs across 10 companies. The most active players are Hyundai Pharmaceutical Co., LTD., Merck & Co., Amyndas Pharmaceuticals S.A.. 8 therapies are approved with 6 more in late-stage development.

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

37/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

94

clinical trials

Completed71 · 76%
Unknown status11 · 12%
Recruiting4 · 4%
Not yet recruiting3 · 3%
Enrolling by invitation3 · 3%
Active, not recruiting2 · 2%

Trial Activity

94 trials

Evaluating Gingivitis and Systemic Biomarkers
Active, not recruiting··Phase 1·NCT06962956·135 enrolled
Assessing Gingivitis and Plaque From a Marketed Toothpaste
Active, not recruiting··Phase 4·NCT07158112·120 enrolled
Homemade Herbal Mouthwash in Gingivitis. A Randomized Clinical Trial.
Not yet recruiting··Phase 3·NCT07401069·12 enrolled
Triphila Mouthwash Effect as Anti-plaque and Anti-gingivitis in Children
Not yet recruiting··Phase 3·NCT07016659·36 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)